NCT00109317View on ClinicalTrials.gov

A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

686

Participants

Timeline

Start Date

September 30, 2002

Study Completion Date

February 28, 2003

Conditions

Psoriasis

Interventions

DRUG

Raptiva (efalizumab)

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY

NCT00109317 - A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy | Biotech Hunter | Biotech Hunter